Cost-effectiveness of a male catch-up human papillomavirus vaccination program in the Netherlands
In the Netherlands, the Health Council has advised that the human papillomavirus (HPV) vaccination should be offered to both boys and girls. Additionally, boys and men up to the age of 26 years should be included in a catch-up program. In this study, we examine the cost-effectiveness of this HPV cat...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-08-01
|
| Series: | Preventive Medicine Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2211335522001796 |
| _version_ | 1818477994493083648 |
|---|---|
| author | Joost J.M. Simons Tjalke A. Westra Maarten J. Postma |
| author_facet | Joost J.M. Simons Tjalke A. Westra Maarten J. Postma |
| author_sort | Joost J.M. Simons |
| collection | DOAJ |
| description | In the Netherlands, the Health Council has advised that the human papillomavirus (HPV) vaccination should be offered to both boys and girls. Additionally, boys and men up to the age of 26 years should be included in a catch-up program. In this study, we examine the cost-effectiveness of this HPV catch-up program.We used a static Markov model to estimate the amount of cancers prevented and the incremental cost-effectiveness ratio (ICER) for different scenarios.Vaccinating men from 12 until the age of 26 years would result in an average of 48 cancer cases prevented in every cohort (an estimated total of 720 cases), with an average ICER of €32,256.We found that the catch-up vaccination program results in a relevant number prevented cases against an acceptable cost-effectiveness ratio. Policymakers should take these findings into account when evaluating a gender-neutral HPV vaccination program in the Netherlands. |
| first_indexed | 2024-12-10T09:43:07Z |
| format | Article |
| id | doaj.art-8224b6d888df4b58b7cbe5794e365112 |
| institution | Directory Open Access Journal |
| issn | 2211-3355 |
| language | English |
| last_indexed | 2024-12-10T09:43:07Z |
| publishDate | 2022-08-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Preventive Medicine Reports |
| spelling | doaj.art-8224b6d888df4b58b7cbe5794e3651122022-12-22T01:53:55ZengElsevierPreventive Medicine Reports2211-33552022-08-0128101872Cost-effectiveness of a male catch-up human papillomavirus vaccination program in the NetherlandsJoost J.M. Simons0Tjalke A. Westra1Maarten J. Postma2Market Access Department, GSK, Van Ash van Wijckstraat 55H, 3811 Amersfoort, the Netherlands; Department of Health Sciences, University of Groningen, University Medical Center, Hanzeplein 1, 9713 GZ Groningen, the Netherlands; Corresponding author at: Market Access Department, GSK, Van Ash van Wijckstraat 55H, 3811 Amersfoort, the Netherlands.Market Access Department, GSK, Van Ash van Wijckstraat 55H, 3811 Amersfoort, the NetherlandsDepartment of Health Sciences, University of Groningen, University Medical Center, Hanzeplein 1, 9713 GZ Groningen, the Netherlands; Unit of Pharmacotherapy, Epidemiology & Economics, University of Groningen, Groningen Research Institute of Pharmacy, A Deusinglaan 1, 9713 AV Groningen, the Netherlands; Department of Economics, Econometrics & Finance, University of Groningen, Faculty of Economics & Business, P.O. Box 800, 9700 AV Groningen, the NetherlandsIn the Netherlands, the Health Council has advised that the human papillomavirus (HPV) vaccination should be offered to both boys and girls. Additionally, boys and men up to the age of 26 years should be included in a catch-up program. In this study, we examine the cost-effectiveness of this HPV catch-up program.We used a static Markov model to estimate the amount of cancers prevented and the incremental cost-effectiveness ratio (ICER) for different scenarios.Vaccinating men from 12 until the age of 26 years would result in an average of 48 cancer cases prevented in every cohort (an estimated total of 720 cases), with an average ICER of €32,256.We found that the catch-up vaccination program results in a relevant number prevented cases against an acceptable cost-effectiveness ratio. Policymakers should take these findings into account when evaluating a gender-neutral HPV vaccination program in the Netherlands.http://www.sciencedirect.com/science/article/pii/S2211335522001796Cost-effectivenessModelingHPVVaccinationCatch-upMale |
| spellingShingle | Joost J.M. Simons Tjalke A. Westra Maarten J. Postma Cost-effectiveness of a male catch-up human papillomavirus vaccination program in the Netherlands Preventive Medicine Reports Cost-effectiveness Modeling HPV Vaccination Catch-up Male |
| title | Cost-effectiveness of a male catch-up human papillomavirus vaccination program in the Netherlands |
| title_full | Cost-effectiveness of a male catch-up human papillomavirus vaccination program in the Netherlands |
| title_fullStr | Cost-effectiveness of a male catch-up human papillomavirus vaccination program in the Netherlands |
| title_full_unstemmed | Cost-effectiveness of a male catch-up human papillomavirus vaccination program in the Netherlands |
| title_short | Cost-effectiveness of a male catch-up human papillomavirus vaccination program in the Netherlands |
| title_sort | cost effectiveness of a male catch up human papillomavirus vaccination program in the netherlands |
| topic | Cost-effectiveness Modeling HPV Vaccination Catch-up Male |
| url | http://www.sciencedirect.com/science/article/pii/S2211335522001796 |
| work_keys_str_mv | AT joostjmsimons costeffectivenessofamalecatchuphumanpapillomavirusvaccinationprograminthenetherlands AT tjalkeawestra costeffectivenessofamalecatchuphumanpapillomavirusvaccinationprograminthenetherlands AT maartenjpostma costeffectivenessofamalecatchuphumanpapillomavirusvaccinationprograminthenetherlands |